4.7 Article

Uncovering the Effect of Passage Number on HT29 Cell Line Based on the Cell Metabolomic Approach

Journal

JOURNAL OF PROTEOME RESEARCH
Volume 20, Issue 3, Pages 1582-1590

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.0c00806

Keywords

metabolomics; HT29 cells; passage number; arginine; synergistic effects

Funding

  1. National Natural Science Foundation of China [81973466, 31270008]

Ask authors/readers for more resources

Increasing cell passage number negatively affects HT29 cells, leading to decreased proliferation and migration ability, as well as distinct metabolomic differences among cells with different passage numbers, with arginine playing a key role in two key metabolic pathways, and exhibiting a synergistic effect with cisplatin.
The passage number is an important factor when designing the cell line-based experiment. Although HT29 cells were widely used in the laboratory for colorectal cancer studies, the impact of cell passage number on the HT29 cells was still unknown. In this study, phenotypic assay and metabolomic approach were applied to analyze the systemic effects of passage numbers (passage 4, 10, and 16) on the HT29 cells. The results showed that the increased cell passage number affected the cell cycle distribution and also decreased the proliferation and migration ability of HT29 cells. The metabolomic analysis coupled with heatmap and hierarchical cluster analysis showed obvious metabolome difference among the cells with different passage numbers, which was related with 61 differential metabolites. Three metabolic pathways were determined as the key pathways, and arginine participated in two of them. In addition, it was found that arginine supplementation could inhibit the proliferation ability of HT29 cells in vitro, and a synergistic effect existed between arginine and cisplatin. In conclusion, this study not only revealed the influence of passage numbers on the HT29 cell but also provided an important reference that arginine has the potential role to be developed as the cisplatin therapeutic adjuvant.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available